Mycoplasma bovis: Pathogenesis, Diagnostics, Epidemiology, and Control in Cattle and Bison

Introduction

Mycoplasma bovis is a cell wall-deficient bacterium of the class Mollicutes and a primary pathogen of cattle worldwide, responsible for significant economic losses due to chronic pneumonia, mastitis, arthritis, and otitis [1, 2, 3]. The organism was first isolated from a case of bovine mastitis in the United States in 1961 and has since been recognized as a core component of the bovine respiratory disease complex (BRDC) in feedlot calves and dairy operations [4]. M. bovis also infects American bison (Bison bison), in which it causes similar clinical syndromes and can persist subclinically without detectable transmission under certain management conditions [5, 6]. A sheep model of M. bovis mastitis has been developed to study host pathogen interactions in a controlled setting [7]. The global prevalence of M. bovis in cattle has been systematically reviewed, with meta-analyses revealing a pooled seroprevalence exceeding 30% in many regions and identifying risk factors such as herd size, purchase of replacement animals, and co-infection with other respiratory pathogens [8, 4].

Taxonomy and Morphology

M. bovis belongs to the hominis phylogenetic group within the genus Mycoplasma. It lacks a cell wall, rendering it intrinsically resistant to beta-lactam antimicrobials and conferring a pleomorphic morphology ranging from coccoid (0.3 to 0.8 μm) to filamentous forms [9]. The genome of M. bovis is approximately 1.0 Mb with a low G+C content (around 29%), encoding a limited repertoire of metabolic enzymes and obligate parasitic dependence on the host for nutrients such as cholesterol and nucleotides [10, 11, 9]. A genetic manipulation tool based on the GP35 recombinase has been developed for targeted gene editing in M. bovis and other ruminant mycoplasmas, enabling functional studies of virulence determinants [11]. Pan-genome analyses of M. bovis isolates from Chinese dairy farms have revealed substantial genomic plasticity, including variable surface lipoprotein genes and integrative conjugative elements (ICEs) that mediate horizontal gene transfer [12, 9]. The diadenylate cyclase CdaM regulates potassium homeostasis in M. bovis and is essential for survival under osmotic stress conditions encountered within the host [13].

Pathogenesis and Virulence Factors

M. bovis employs a multifactorial strategy to colonize and persist within the bovine respiratory and mammary epithelia. The pyruvate dehydrogenase complex (PDH) has been characterized as a cytoadhesin that binds host extracellular matrix components such as fibronectin and collagen, facilitating attachment to epithelial cells [14]. The leucine-rich repeat protein LRR5 is a key invasion protein that interacts with host cytoskeletal elements to promote internalization into non-phagocytic cells [15]. Once internalized, M. bovis can survive intracellularly, evading both humoral and cellular immune responses [16]. The organism modulates host cell signaling by altering the cargo of small extracellular vesicles (sEVs) derived from bovine endometrial epithelial cells; these sEVs carry host inflammatory proteins that are distinct from those in uninfected cells [17, 18]. The deoC gene of M. bovis encodes a deoxyribose-phosphate aldolase involved in nucleoside catabolism, which is critical for salvaging purines and pyrimidines from the host environment and contributes to survival within macrophages [10]. Host lipid metabolism is also perturbed during M. bovis pneumonia, as demonstrated by untargeted lipidomics showing altered phospholipid and sphingolipid profiles in plasma of infected calves [19]. Fenofibrate, a PPAR-alpha agonist, suppresses M. bovis infection in bovine mammary epithelial cells and murine mammary tissue by inducing autophagy-mediated cholesterol regulation, suggesting a potential host-directed therapeutic avenue [20].

Clinical Syndromes

Bovine Respiratory Disease

The most common manifestation of M. bovis infection is chronic, caseonecrotic bronchopneumonia in feedlot and dairy calves, often occurring as a component of BRDC [3, 21]. Deep nasopharyngeal swabs and non-endoscopic bronchoalveolar lavage in calves on farms with a history of bronchopneumonia frequently yield M. bovis in mixed infection with other bacteria such as Histophilus somni and Pasteurella multocida [21]. Clinical signs include fever, depression, tachypnea, coughing, and nasal discharge. Pathologically, affected lungs exhibit consolidated, necrotic foci with a characteristic caseous exudate.

Mastitis

M. bovis is a well-recognized cause of contagious mastitis in dairy cattle, especially in large herds. Subclinical mastitis can persist for months, leading to elevated bulk tank somatic cell counts and reduced milk yield [22, 23]. Therapeutic vaccination with a live M. bovis-BoAHV-1 combined vaccine has been shown to accelerate pathogen clearance and restore mammary homeostasis in naturally infected cows with subclinical mastitis [22].

Arthritis and Otitis

Polyarthritis is a frequent sequel to respiratory infection in calves, characterized by lameness, joint swelling, and synovial fluid containing M. bovis. Otitis media, particularly in neonatal calves, is associated with head tilt, ear droop, and hearing loss.

Infection in Bison

In North American bison, M. bovis causes severe respiratory disease and has been linked to herd-level outbreaks. A case-control survey of bison herds revealed that M. bovis seropositivity is associated with high morbidity and mortality rates [5]. Subclinical infections can persist in bison populations without detectable horizontal transmission under low-density conditions, complicating eradication efforts [6].

Epidemiology and Transmission

M. bovis is transmitted primarily via direct contact through respiratory aerosols and secretions, as well as through contaminated milk and fomites [2, 3]. Bulk tank milk ELISA can be used as a screening test for herd-level classification, with confirmatory PCR testing of different age groups recommended to differentiate active from historical infections [23]. Spatiotemporal modeling of M. bovis infection in mainland China has identified high-risk clusters in the eastern and central provinces, with risk factors including cattle density, farm size, and inter-provincial animal movement [2]. Herd-level prevalence of M. bovis antibodies in Austrian dairy herds, measured in bulk tank milk, was 27.3% and was significantly associated with purchasing cattle from multiple sources and having concurrent respiratory disease [8]. The pathogen has also been detected in raw bovine semen from artificial insemination centers in the United States, raising concerns about venereal transmission and introduction into naive herds [24]. In southern Brazil, molecular detection of M. bovis and other Mollicutes in the reproductive system of cattle over a three-year period indicated a 12% prevalence in vaginal swabs and preputial washings [25].

Laboratory Diagnosis

Culture and Isolation

M. bovis is fastidious and requires enriched media (e.g., Hayflick's or Friis broth) supplemented with 10–20% horse serum and yeast extract. Colonies on solid medium exhibit a characteristic "fried egg" appearance. Isolation is time-consuming and often yields false-negative results due to overgrowth by faster-growing bacteria or prior antimicrobial therapy [26].

Polymerase Chain Reaction and Sequencing

Real-time PCR and conventional PCR targeting the uvrC gene or 16S rRNA are widely used for direct detection in milk, nasal swabs, bronchoalveolar lavage fluid, and tissue homogenates [26]. A SYBR Green qPCR assay developed for Chinese beef cattle isolates shows high analytical sensitivity and specificity [26]. Multiplex PCR combined with nanopore sequencing has been applied for rapid detection and surveillance of antimicrobial resistance (AMR) genes in M. bovis from Japanese dairy cattle, enabling simultaneous identification of the pathogen and its resistance determinants [1].

Serology

Commercial ELISA kits are available for detection of anti-M. bovis antibodies in serum, milk, and nasopharyngeal swab fluid [27, 28]. A P48-based ELISA has been evaluated in North American bison but showed inferior performance compared to a commercially available whole-cell ELISA [28]. A time-resolved fluorescent lateral flow immunochromatographic strip test has been developed for rapid detection of antibodies under field conditions [29]. Bulk tank milk ELISA has been validated as a herd-level screening tool with high sensitivity (91%) and moderate specificity (79%) [23].

Metabolomics and Proteomics

Plasma metabolomics using free amino acid and fatty acid profiling has been applied to Simmental calves naturally infected with M. bovis, revealing alterations in energy and lipid metabolism that may serve as biomarkers for disease severity [30]. The development of a real-time metabolic kinetic system based on redox and pH indicators has enabled monitoring of M. bovis metabolic activity in culture, facilitating antibiotic susceptibility testing [31]. Targeted metagenomics approaches using enrichment of M. bovis sequences from milk samples have been evaluated in silico and show promise for strain-level differentiation without culture [32].

Antimicrobial Resistance

M. bovis is intrinsically resistant to beta-lactams and polymyxins due to its lack of a cell wall. Acquired resistance to tetracyclines, macrolides, and fluoroquinolones is increasingly reported worldwide. Integrative and conjugative elements (ICEs) harboring tet(M), erm(42), and aphA3 genes have been characterized in M. bovis isolates from Western Canadian feedlot cattle, and conjugative transfer of these ICEs to other mycoplasma species has been demonstrated in vitro [12]. Whole-genome sequencing of M. bovis from Chinese dairy farms revealed a high prevalence of macrolide resistance mutations (23S rRNA) and the presence of a novel type II topoisomerase mutation conferring fluoroquinolone resistance [9]. The multiplex PCR-nanopore sequencing platform described in [1] allows simultaneous detection of AMR genes and the organism itself, providing a surveillance tool for guiding antimicrobial stewardship.

Vaccines and Immune Control

Vaccination against M. bovis has been challenging due to the organism's ability to evade immune responses through antigenic variation, biofilm formation, and intracellular survival [16]. A combined live vaccine containing M. bovis and bovine alphaherpesvirus type 1 (BoAHV-1) has been developed and shown to enhance immune protection in dairy cattle when co-administered with Escherichia coli Nissle 1917 as an immunomodulator [33]. The same combined vaccine, when used therapeutically, accelerated clearance of M. bovis from milk and restored mammary epithelial integrity in cows with subclinical mastitis [22]. Reverse vaccinology integrated with pan-genome analysis has identified conserved vaccine targets, including lipoproteins and membrane transporters, which induced robust antibody responses and were safe in mice [34]. A systematic review of vaccines for bovine respiratory mycoplasmas highlighted the lack of a universally effective commercial vaccine and emphasized the need for more efficacious formulations that induce mucosal and cellular immunity [3].

Control and Eradication

Control strategies for M. bovis rely on biosecurity, herd monitoring, and management practices. Swedish cattle farmers' preferences for control measures, assessed through a discrete choice experiment, indicate a strong willingness to implement testing and segregation of purchased animals if the cost is subsidized [35]. Bulk tank milk PCR and ELISA are cost-effective screening methods for early detection of infected herds [23]. Eradication from infected herds is difficult due to subclinical carriers and persistence in the environment; however, depopulation or whole-herd testing with culling of seropositive animals has been successful in some regions.

Diagnostic Algorithm

The following Mermaid diagram outlines a recommended diagnostic workflow for M. bovis infection in cattle:

flowchart TD
    A[Clinical suspicion: respiratory disease, mastitis, arthritis], > B[Sample collection]
    B, > C[Milk, nasal swab, BAL, joint fluid, or tissue]
    C, > D[Initial screening: Commercial ELISA for antibodies in serum/milk]
    D, > E{Positive or ambiguous result?}
    E, >|Yes| F[Confirm by PCR on same sample type]
    E, >|No| G[Low likelihood; consider other pathogens]
    F, > H{Detection of M. bovis DNA?}
    H, >|Yes| I[Confirmed infection; perform antimicrobial susceptibility testing]
    H, >|No| J[False-positive serology; consider past exposure]
    I, > K[Whole-genome sequencing or targeted AMR genotyping]
    K, > L[Informed treatment and biosecurity decisions]

Frequently Asked Questions

What is Mycoplasma bovis?

Mycoplasma bovis is a cell wall-less bacterium within the class Mollicutes that causes chronic pneumonia, mastitis, arthritis, and otitis in cattle and bison, and is a major contributor to the bovine respiratory disease complex (BRDC) [1, 3, 4].

How is Mycoplasma bovis transmitted?

Transmission occurs primarily through direct contact with respiratory secretions, contaminated milk, and fomites; venereal transmission through semen is also possible [2, 24, 25].

What are the clinical signs of Mycoplasma bovis infection in cattle?

Clinical signs include fever, chronic cough, nasal discharge, decreased feed intake, lameness with swollen joints, and udder abnormalities such as agalactia and fibrosis [30, 22, 21].

How is Mycoplasma bovis diagnosed?

Diagnosis is confirmed by culture, PCR of respiratory or milk samples, or serological ELISA; multiplex PCR combined with nanopore sequencing may simultaneously detect AMR genes [1, 26, 23, 28].

What treatments are available for Mycoplasma bovis?

Antimicrobials such as florfenicol, enrofloxacin, oxytetracycline, and tulathromycin are used, but resistance is increasing; host-directed therapies like fenofibrate are under investigation [1, 12, 9, 20].

Is there a vaccine for Mycoplasma bovis?

A live combined vaccine with BoAHV-1 and immunomodulatory E. coli Nissle 1917 is available in some regions; reverse vaccinology approaches have identified conserved targets for future subunit vaccines [33, 22, 34].

What is the global prevalence of Mycoplasma bovis?

Systematic reviews and meta-analyses report a global seroprevalence of 28% to 60% depending on region, with higher rates in dairy than beef herds [2, 8, 4].

References

[1] Usui M, Ebisawa M, Okamura S et al. Application of multiplex PCR-based nanopore sequencing for rapid detection and surveillance of antimicrobial-resistant Mycoplasma bovis in Japanese dairy cattle. Microbiol Spectr. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42390089/

[2] Su Y, Zhao G, Xu J et al. Spatiotemporal modeling of Mycoplasma bovis infection and risk factors in cattle across mainland China: Implications for disease control and surveillance. J Dairy Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42217786/

[3] Werid GM, Ibrahim YM, Wubshet AK et al. Bovine Respiratory Mycoplasmas and the Commensal-Pathogen Continuum: A Systematic Review of Vaccines and Diagnostic Approaches. Animals (Basel). 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41897937/

[4] Zhang S, Liu G, Yu F et al. Integrated meta-analysis and sentinel surveillance: Global prevalence and risk factors for Mycoplasma bovis in cattle (2007-2023). One Health. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41552423/

[5] Martin KA, Browne AS, Buttke DE. Corrigendum to "Mycoplasma bovis outbreaks in United States bison (Bison bison) herds: A case-control survey" [Prev. Vet. Med. 243 (2025) 106597]. Prev Vet Med. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41765711/

[6] Buttke DE, Kaplan BS, Jones LC et al. Maintenance of Subclinical Mycoplasma bovis Infections in American Bison (Bison bison) in the Absence of Detectable Transmission. J Wildl Dis. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41638609/

[7] Wawegama NK, Kanci Condello A, Salgadu A et al. Development of a sheep model of mastitis caused by Mycoplasma bovis. Vet Microbiol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42142483/

[8] Laschinger J, Wieser H, Hoop P et al. Herd-level prevalence of Mycoplasma bovis antibodies in bulk tank milk samples in Austrian dairy herds and risk factors associated with herd seropositive status. Vet Res Commun. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41721920/

[9] Wu C, Sun X, Wu Y et al. Mycoplasma bovis isolates from Chinese dairy farms: Analysis of genomic features, antimicrobial resistance, and virulence-associated structural differences. Vet Microbiol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41650486/

[10] Geng S, Elahee Doomun SN, Hondrogiannis J et al. Role of the Mycoplasma bovis deoC gene in nucleoside catabolism and host cell survival. Appl Environ Microbiol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42117702/

[11] Lan S, Li Z, Jing T et al. A genetic manipulation tool based on the GP35 recombinase for targeted gene editing in mycoplasmas of ruminants. J Biol Chem. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42055338/

[12] Andres-Lasheras S, Zaheer R, Ortega-Polo R et al. Integrative and conjugative elements in Mycoplasmopsis bovis from Western Canadian feedlot cattle: characterization and conjugative transfer. Front Vet Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41684385/

[13] Chen J, Lu D, Fu Y et al. Regulation of potassium homeostasis in Mycoplasma bovis by the diadenylate cyclase CdaM. Front Microbiol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41909269/

[14] Cui W, Lan S, Li Z et al. The pyruvate dehydrogenase complex as a cytoadhesin in Mycoplasma bovis that binds host extracellular matrix components. Int J Biol Macromol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41759839/

[15] Zhou M, Feng Y, Li Y et al. Screening and functional validation of host interacting proteins for the key invasion protein LRR5 of Mycoplasma bovis. Microb Pathog. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41707840/

[16] Yu C, Ma Z, Yu H et al. Navigating immune evasion: The quest for an effective Mycoplasma bovis vaccine. Microb Pathog. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41861973/

[17] Ross MA, Maes E, Lake AVR et al. Inflammation markers are associated with small extracellular vesicle protein signatures in cows with Mycoplasma bovis. Front Vet Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42221946/

[18] Pratt JT, Lake AVR, Maes E et al. Mycoplasma bovis infection alters small extracellular vesicle cargo derived from bovine endometrial epithelial cells cultured in static bioreactors. Front Microbiol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42182006/

[19] Yang F, Liu F, Zhai Y et al. Plasma untargeted lipidomics based on UHPLC-Orbitrap-MS reveals potential biomarkers and the pathogenesis involved in Mycoplasma bovis pneumonia. Vet Microbiol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41719760/

[20] Xu M, Wang T, Deng X et al. Fenofibrate suppresses Mycoplasma bovis infection via autophagy-mediated cholesterol regulation in bovine mammary epithelial cells and murine mammary tissue. Front Cell Infect Microbiol. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41602117/

[21] Laschinger J, Spergser J, Taxacher B et al. Bacteria identified from deep nasopharyngeal swabs and non-endoscopic bronchoalveolar lavage in calves on farms with a history of bronchopneumonia. Acta Vet Scand. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41832584/

[22] Zhang S, Liu G, Cao H et al. Therapeutic vaccination with a live M. bovis-BoAHV-1 combined vaccine accelerates pathogen clearance and restores mammary homeostasis in dairy cows with natural Mycoplasma bovis subclinical mastitis. BMC Microbiol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41942861/

[23] Vandewalle J, van Mol W, Bokma J et al. Bulk tank milk ELISA as screening test for Mycoplasma bovis: herd classification based on serology and PCR testing of different age groups. Ir Vet J. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41547918/

[24] Caflisch EA, Pellegrini FV, Georgousi F et al. Prevalence of Mycoplasmopsis bovis and Histophilus somni in raw bovine semen from artificial insemination collection centers in the United States. J Dairy Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41937057/

[25] Wessely HCA, Dotto EK, Costa ASMD et al. Molecular detection of Mollicutes agents in reproductive system of cattle: a three-year study in Rio Grande do Sul, southern Brazil (2022-2024). Trop Anim Health Prod. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41784871/

[26] Wang G, Li Y, Liu L et al. Isolation, Identification, and Molecular Characterization of Mycoplasma bovis from Beef Cattle in Kunming, and Development of a SYBR Green qPCR Assay. Pathogens. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41754415/

[27] Dudley EP, Hunt BO, Valeris-Chacin R. Detection of anti-Mycoplasma bovis IgG in bovine nasopharyngeal swabs. Front Vet Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42368349/

[28] Krus CB, Nehring M, Kaplan BS et al. Evaluation of a P48 ELISA for Mycoplasmopsis (Mycoplasma) bovis in North American bison (Bison bison): inferior performance compared to a commercially available ELISA. BMC Vet Res. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41530814/ *** Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.

[29] Du YT, Wang LY, Zhu C et al. Development of a time-resolved fluorescent lateral flow immunochromatographic strip for detection of Mycoplasma bovis antibodies. Anal Biochem. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41825705/

[30] Gazioğlu A, Okutan T, Yilmaz Ö. Evaluation of Free Amino Acid and Fatty Acid Concentrations in Simmental Calves Naturally Infected With Mycoplasma bovis Using a Metabolomics Approach. Vet Med Int. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42367584/

[31] Kanda T, Uemura R, Ito K et al. Development of a real-time metabolic kinetic system for monitoring redox and pH transitions in Mycoplasma bovis. J Microbiol Methods. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42217634/

[32] Biesheuvel MM, Barkema HW, Morley PS et al. In silico performance of a targeted enriched metagenomics approach to infer Mycoplasma bovis strains in milk. Front Vet Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41929272/

[33] Zhang S, Liu G, Chen J et al. Enhancing immune protection in dairy cattle: role of Escherichia coli Nissle 1917 in boosting the efficacy of a Mycoplasma bovis-BoAHV-1 combined vaccine. mSphere. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42029038/

[34] Mu J, Ma Z, Li J et al. Identification of conserved vaccine targets in Mycoplasma bovis through integrated pan-genome and reverse vaccinology approaches with in vivo immunogenicity and safety evaluation. Vet J. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41720456/

[35] Tao H, Ewerlöf IR, Stengärde L et al. Swedish cattle farmers' preferences for control measures against Mycoplasma bovis: A discrete choice experiment. Prev Vet Med. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42114412/